Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders

Takefumi Ishii, Jiapeng Wang, Wei Zhang, John Mascarenhas, Ronald Hoffman, Ying Dai, Nathaniel Wisch, Mingjiang Xu

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Pruritus is a common symptom in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs). The pathophysiology of MPD-associated pruritus is unclear. We have demonstrated that MPD mast cells (MCs) are involved by the malignant process. In the present study, we explored the hypothesis that MCs play an important role in the development of pruritogenesis in MPDs. We found that MPD MCs released significantly greater amounts of pruritogenic factors, including histamine, leukotrienes, and interleukin-31 (IL-31) than normal MCs. Elevated levels of IL-31 were also observed in MPD CD3+ cell-conditioned media. MPD MCs exhibited increased migratory behavior in response to stem cell factor or interleukin-8, which was associated with increased filamentous-actin content. Furthermore, the presence of pruritus in MPDs was statistically correlated with a greater number of MCs being generated by CD34+ cells, a greater number of MC colonies being formed by CD34+ cells, decreased apoptosis and prostaglandin D2 release by cultured MCs, and higher plasma levels of IL-31. These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs.

Original languageEnglish (US)
Pages (from-to)5942-5950
Number of pages9
JournalBlood
Volume113
Issue number23
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Myeloproliferative Disorders
Interleukins
Mast Cells
Prostaglandin D2
Stem Cell Factor
Leukotrienes
Chromosomes
Conditioned Culture Medium
Interleukin-8
Histamine
Actins
Pruritus
Apoptosis
Plasmas
Pharmaceutical Preparations
Philadelphia Chromosome
Cultured Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ishii, T., Wang, J., Zhang, W., Mascarenhas, J., Hoffman, R., Dai, Y., ... Xu, M. (2009). Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood, 113(23), 5942-5950. https://doi.org/10.1182/blood-2008-09-179416

Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. / Ishii, Takefumi; Wang, Jiapeng; Zhang, Wei; Mascarenhas, John; Hoffman, Ronald; Dai, Ying; Wisch, Nathaniel; Xu, Mingjiang.

In: Blood, Vol. 113, No. 23, 2009, p. 5942-5950.

Research output: Contribution to journalArticle

Ishii, T, Wang, J, Zhang, W, Mascarenhas, J, Hoffman, R, Dai, Y, Wisch, N & Xu, M 2009, 'Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders', Blood, vol. 113, no. 23, pp. 5942-5950. https://doi.org/10.1182/blood-2008-09-179416
Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113(23):5942-5950. https://doi.org/10.1182/blood-2008-09-179416
Ishii, Takefumi ; Wang, Jiapeng ; Zhang, Wei ; Mascarenhas, John ; Hoffman, Ronald ; Dai, Ying ; Wisch, Nathaniel ; Xu, Mingjiang. / Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. In: Blood. 2009 ; Vol. 113, No. 23. pp. 5942-5950.
@article{e82e7018fa7a4daeb151bdebca4c6267,
title = "Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders",
abstract = "Pruritus is a common symptom in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs). The pathophysiology of MPD-associated pruritus is unclear. We have demonstrated that MPD mast cells (MCs) are involved by the malignant process. In the present study, we explored the hypothesis that MCs play an important role in the development of pruritogenesis in MPDs. We found that MPD MCs released significantly greater amounts of pruritogenic factors, including histamine, leukotrienes, and interleukin-31 (IL-31) than normal MCs. Elevated levels of IL-31 were also observed in MPD CD3+ cell-conditioned media. MPD MCs exhibited increased migratory behavior in response to stem cell factor or interleukin-8, which was associated with increased filamentous-actin content. Furthermore, the presence of pruritus in MPDs was statistically correlated with a greater number of MCs being generated by CD34+ cells, a greater number of MC colonies being formed by CD34+ cells, decreased apoptosis and prostaglandin D2 release by cultured MCs, and higher plasma levels of IL-31. These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs.",
author = "Takefumi Ishii and Jiapeng Wang and Wei Zhang and John Mascarenhas and Ronald Hoffman and Ying Dai and Nathaniel Wisch and Mingjiang Xu",
year = "2009",
doi = "10.1182/blood-2008-09-179416",
language = "English (US)",
volume = "113",
pages = "5942--5950",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders

AU - Ishii, Takefumi

AU - Wang, Jiapeng

AU - Zhang, Wei

AU - Mascarenhas, John

AU - Hoffman, Ronald

AU - Dai, Ying

AU - Wisch, Nathaniel

AU - Xu, Mingjiang

PY - 2009

Y1 - 2009

N2 - Pruritus is a common symptom in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs). The pathophysiology of MPD-associated pruritus is unclear. We have demonstrated that MPD mast cells (MCs) are involved by the malignant process. In the present study, we explored the hypothesis that MCs play an important role in the development of pruritogenesis in MPDs. We found that MPD MCs released significantly greater amounts of pruritogenic factors, including histamine, leukotrienes, and interleukin-31 (IL-31) than normal MCs. Elevated levels of IL-31 were also observed in MPD CD3+ cell-conditioned media. MPD MCs exhibited increased migratory behavior in response to stem cell factor or interleukin-8, which was associated with increased filamentous-actin content. Furthermore, the presence of pruritus in MPDs was statistically correlated with a greater number of MCs being generated by CD34+ cells, a greater number of MC colonies being formed by CD34+ cells, decreased apoptosis and prostaglandin D2 release by cultured MCs, and higher plasma levels of IL-31. These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs.

AB - Pruritus is a common symptom in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs). The pathophysiology of MPD-associated pruritus is unclear. We have demonstrated that MPD mast cells (MCs) are involved by the malignant process. In the present study, we explored the hypothesis that MCs play an important role in the development of pruritogenesis in MPDs. We found that MPD MCs released significantly greater amounts of pruritogenic factors, including histamine, leukotrienes, and interleukin-31 (IL-31) than normal MCs. Elevated levels of IL-31 were also observed in MPD CD3+ cell-conditioned media. MPD MCs exhibited increased migratory behavior in response to stem cell factor or interleukin-8, which was associated with increased filamentous-actin content. Furthermore, the presence of pruritus in MPDs was statistically correlated with a greater number of MCs being generated by CD34+ cells, a greater number of MC colonies being formed by CD34+ cells, decreased apoptosis and prostaglandin D2 release by cultured MCs, and higher plasma levels of IL-31. These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs.

UR - http://www.scopus.com/inward/record.url?scp=67651120136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651120136&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-09-179416

DO - 10.1182/blood-2008-09-179416

M3 - Article

VL - 113

SP - 5942

EP - 5950

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -